title: Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
authors.affiliation: Department of Physician Assistant Studies, East Carolina University, Greenville, North Carolina, USA Vidant Medical Center, Greenville, North Carolina, USA.
authors.forename: Martin
authors.initials: M
authors.lastname: Mayer
mesh_terms: D000627:Aminophenols / Q000009:adverse effects / Q000627:therapeutic use*; D000631:Aminopyridines / Q000009:adverse effects / Q000627:therapeutic use*; D052117:Benzodioxoles / Q000009:adverse effects / Q000627:therapeutic use*; D015992:Body Mass Index; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D017277:Drug Approval; D004338:Drug Combinations; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D008168:Lung / Q000503:physiopathology; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000627:Aminophenols; D000631:Aminopyridines; D052117:Benzodioxoles; D004338:Drug Combinations; D015363:Quinolones; C000599212:lumacaftor, ivacaftor drug combination
keywords: RESPIRATORY MEDICINE (see Thoracic Medicine); STATISTICS & RESEARCH METHODS; THERAPEUTICS; THORACIC MEDICINE